Ascletis Pharma Inc. announces the poster presentation of ASC42, a novel farnesoid X receptor agonist, in combination with PEGylated interferon and entecavir in chronic hepatitis B patients with 12-week treatment at European Association for the Study of the Liver CONGRESS 2023.
